SAM, CAM act on acquisition of Derma and Nephrology biz units of Biocon Biologics by Eris Lifesciences

Eris Lifesciences Limited has acquired the Dermatology and Nephrology branded formulations business units of Biocon Biologics Limited in India for approximately ₹366 crore.

The transaction is a ‘Slump Sale’ that will enable a seamless transfer of the product brands and employees associated with these businesses.

Shardul Amarchand Mangaldas & Co advised Eris Lifesciences on this acquisition deal.

The transaction team was led by Nivedita Tiwari (Partner), Shailesh Singh (Principal Associate) and Anupama Singh (Senior Associate).

The employment law team was led by Pooja Ramchandani (Partner) and Suruchi Kumar (Principal Associate).

The IP law team was led by Apoorva Murali (Partner) and Neha Khanduri (Senior Associate).

The tax team was led by Amit Singhania (Partner), Ankita Bhasin (Counsel), Rahul Yadav (Counsel) and Mansie Jain (Associate).

The competition law team was led by Harman Singh Sandhu (Partner), Raveena Kumari Sethia (Senior Associate) and Abhishek Hazari (Associate).

Eris Lifescience is a long standing client of Shardul Amarchand and the Firm's Capital Markets Partner Prashant Gupta is on the Board of Eris.

Cyril Amarchand Mangaldas advised Biocon Biologics on this deal.

This acquisition marks the entry of Eris into Nephrology, and also enables Eris to consolidate its position in Dermatology.

If you would like your Deals, Columns, Press Releases to be published on Bar & Bench, please fill in the form available here.